Liquidia (LQDA -8.49%) hasn't been the healthiest healthcare stock on the exchange over the past few days. On Wednesday, the commercial-stage biotech published a quarterly earnings report that led to a pronounced sell-off; as of early Friday morning, its shares were down by 20% week to date.
Yutrepia for the win
In its second quarter, Liquidia's revenue totaled almost $171.7 million, far higher than the $8.8 million it posted in the same period of 2025. That sharp rise was due almost entirely to increases in sales volume of the company's lone commercialized drug, the pulmonary hypertension treatment Yutrepia, which hit the market in June of that year.
Image source: Getty Images.
On the bottom line, Liquidia flipped to a net profit under generally accepted accounting principles (GAAP) of $74.7 million ($0.74 per share), from the year-ago loss of $41.6 million.
Although the company edged past the consensus analyst estimate of just under $171 million, it slightly missed the $0.76-per-share net income forecast.
Liquidia updated the progress of its one remaining developmental program, that for L-606. This medication uses the same molecule as Yutrepia and targets the same affliction. However, it has a different formulation and delivery method.
NASDAQ: LQDA
Key Data Points
Inflated expectations
That bottom-line miss barely counts as a miss at all, given its tiny size. What happened with Liquidia was that its stock had risen so steeply -- it was up 155% year-to-date prior to earnings -- that nothing short of a crushing, blowout quarter would have sustained the momentum.
The only other concern apparent to me is the potential one-trick pony aspect of Liquidia's one favored molecule. So far, though, Yutrepia is doing quite well, and this company has a brighter future than that post-earnings decline would suggest.
